LUNG: הכנסות ממכירות החברה Pulmonx

Pulmonx Corporation (LUNG) has achieved a breakthrough by developing minimally invasive systems for the treatment of severe emphysema. Reviewing the company's sales performance on GURU.Markets, it is evident how the value of 0.09 describes the current revenue level. Growth is driven by strong pricing power within pulmonology, while Zephyr's status as a medical standard and its insurance coverage create a powerful defensive moat for the business.
פילוחי מדדים מקיפים ואנליטיקה עבור Pulmonx (LUNG)

The deployment of robotic lines and AI modules at Pulmonx Corporation (LUNG) directly scales the commercial potential of its medical valves. This metric aggregates total cash inflows from core operations, measuring real market demand for high-tech products. Revenue dynamics determine the issuer's financial stability and allow for the timely detection of cash flow stagnation. Analyzing the company's sales volume helps investors accurately identify entry points, avoiding the purchase of the asset at its peak.